Literature DB >> 11353300

Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis.

S B Solomon1, A Semih Dogan, T L Nicol, J N Campbell, M G Pomper.   

Abstract

Benign neurofibromas undergo sarcomatous transformation in approximately 5% of patients with neurofibromatosis type I. The clinical and radiologic diagnosis of sarcomatous change remains difficult. Positron emission tomography with F-18 fluorodeoxyglucose is a method to assess increased glucose metabolism in malignant tissue such as sarcomas. In this case report, positron emission tomography accurately distinguished malignant from benign neurofibromas. The technique may be useful as a noninvasive screening tool for malignant transformation of neurofibromas.

Entities:  

Mesh:

Year:  2001        PMID: 11353300     DOI: 10.1097/00003072-200106000-00009

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  10 in total

Review 1.  MR imaging of soft tissue tumors and tumor-like lesions.

Authors:  Tal Laor
Journal:  Pediatr Radiol       Date:  2003-12-12

2.  The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression.

Authors:  Michael J Fisher; Sandip Basu; Eva Dombi; Jian Q Yu; Brigitte C Widemann; Avrum N Pollock; Avital Cnaan; Hongming Zhuang; Peter C Phillips; Abass Alavi
Journal:  J Neurooncol       Date:  2007-12-11       Impact factor: 4.130

3.  Use of chemical shift encoded magnetic resonance imaging (CSE-MRI) for high resolution fat-suppressed imaging of the brachial and lumbosacral plexuses.

Authors:  Allison Grayev; Scott Reeder; Amgad Hanna
Journal:  Eur J Radiol       Date:  2016-04-11       Impact factor: 3.528

4.  Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.

Authors:  Winfried Brenner; Reinhard E Friedrich; Karim A Gawad; Christian Hagel; Andreas von Deimling; Maike de Wit; Ralph Buchert; Malte Clausen; Victor F Mautner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-11       Impact factor: 9.236

5.  Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI.

Authors:  Akihiko Matsumine; K Kusuzaki; T Nakamura; S Nakazora; R Niimi; T Matsubara; K Uchida; T Murata; I Kudawara; T Ueda; N Naka; N Araki; M Maeda; A Uchida
Journal:  J Cancer Res Clin Oncol       Date:  2008-12-20       Impact factor: 4.553

6.  FDG PET/CT detects benign neurofibromas presenting as nodal masses: Imaging hallmarks of a diagnostic "red herring".

Authors:  Ameya D Puranik; Nilendu C Purandare; Munita M Bal; Archi Agrawal; Sneha Shah; Venkatesh Rangarajan
Journal:  Indian J Nucl Med       Date:  2015 Apr-Jun

7.  Fluorine-18-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography Masquerading as a Case of Sporadic Malignant Peripheral Nerve Sheath Tumor of Lower Extremity Presenting as Massive Lower Limb Edema.

Authors:  Deepa Singh; Rajender Kumar; Ashim Das; Subhash C Varma; Bhagwant R Mittal
Journal:  World J Nucl Med       Date:  2017 Oct-Dec

8.  The correlation between clinical, nuclear and histologic findings in a patient with Von Recklinghausen's disease.

Authors:  Justus-Martijn Brinkman; Johannes L Bron; Paul Ijm Wuisman; Paul J van Diest; Emile Fi Comans; Carla Fm Molthoff
Journal:  World J Surg Oncol       Date:  2007-11-12       Impact factor: 2.754

9.  Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.

Authors:  Mehdi Brahmi; Philippe Thiesse; Dominique Ranchere; Thomas Mognetti; Stephane Pinson; Caroline Renard; Anne-Valérie Decouvelaere; Jean-Yves Blay; Patrick Combemale
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

10.  Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1.

Authors:  Patrick Combemale; Laurence Valeyrie-Allanore; Francesco Giammarile; Stephane Pinson; Bernard Guillot; Denis Mariano Goulart; Pierre Wolkenstein; Jean Yves Blay; Thomas Mognetti
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.